REASSURE: Radium-223 Alpha Emitter Agent in Non-Interventional Safety Study in Metastatic Castrate Presistant Prostate Cancer Population for Long-Term Evaluation 
Aims:The purpose of the study is to evaluate the short and long term safety profile of Radium-223 under routine practice conditions. The study was initiated and is financed by Bayer HealthCare Pharmaceuticals Inc. This includes payment of a reimbursement to your doctor and his/her team for the cost of the study. Bayer HealthCare Pharmaceuticals, Inc. may hire contract service providers to support in the performance of the study. 
Principal Investigator: Daniel Shevrin, MD
IRB Approval Number: EH14-261
Sponsor:Bayer HealthCare Pharmaceuticals, Inc. 
Contact: Interested patients should contact research nurse Tara Flanagan at 847.570.1768
Open to Enrollment: Yes

MOSAIC-P: Mindfulness Online for Symptom Alleviation and Improvement in Cancer of the Prostate 
Aims:The purpose of the study is to test a four-week mindfulness program that is intended to reduce stress and improve the quality of life in men with prostate cancer that has spread to other parts of the body.   Each participant will be separated into one of two meeting locations at random, although the class content will be the same. Classes will be held: 1) in-person at a NorthShore facility;  or 2) online allowing men to participate while staying at home. 
Principal Investigator: Britt Hanson, DO
IRB Approval Number: EH15-403
Sponsor: NorthShore University HealthSystem 
Contact: Interested patients should contact study coordinator Nick Kirwen at 847.503.4281
Open to Enrollment: Yes

3104007: A Multinational, Randomized, Double-Blind, Placebo-Controlled, Phase III Efficacy and Safety Study of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostrate Cancer
Aims: The purpose of this study is to assess the safety and effectiveness of the study drug ODM-201 compared to placebo (a dummy medication that looks like the real medication but has no active ingredients) in men with prostate cancer who have recurrence of disease despite hormone therapy and no evidence of metastasis (no evidence that cancer has spread to other areas of the body). The study treatment will be given in conjunction with your current hormonal treatment, if you have been prescribed such treatment. ODM-201 is a new investigational drug being developed for men who have no evidence that their cancer has spread to other areas of the body, but who have high risk of their cancer spreading.
Principal Investigator: Daniel Shevrin, MD
IRB Approval Number: EH14-156
Sponsor: Bayer HealthCare Pharmaceuticals, Inc.
Contact: Interested patients should contact research nurse Tara Flanagan at 847.570.1768
Open to Enrollment: Yes

PCCTC c13-126: A Randomized Phase II Randomized Prospective Trial of Docetaxel/Prednisone Versus Docetaxel/Prednisone and Enzalutamide in Castration-Resistant Prostate Cancer (CRPC) Patients Progressingon Enzalutamide
Aims: The main purpose is to study whether the addition of enzalutamide to the current standard chemotherapy (docetaxel and prednisone) works better in men than teh standard chemotherapy alone.
Principal Investigator: Daniel Shevrin, MD
IRB Approval Number: EH16-209
Sponsor: University of Chicago/PCCTC
Contact: Interested patients should contact research nurse Tara Flanagan at 847.570.1768
Open to Enrollment: Yes

SPORE: Tissue, Blood, and Urine Banking for the Robert H. Lurie Comprehensive Cancer Center Prostate Tissue Bank
Aims: This study involves the banking (storing) of prostate tissue, blood and urine. Information from the patient's medical records and treatment will be followed for an indefinite amount of time up to 75 years or more. The purpose of the study is to enable cancer researchers and other investigators attain a better understanding of the development of prostate cancer, its treatment, prevention, and cure.
Diagnosis: Prostate
Principal Investigator: Daniel Shevrin, MD
IRB Approval Number: EH01-129
Sponsor: Robert H. Lurie Comprehensive Cancer Center
Contact: Interested patients should contact research nurse Tara Flanagan at 847.570.1768
Open to Enrollment: Yes

S1216: A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer
Aims: The purpose of this study is to find out what effects (good and/or bad) there are to adding the new investigational drug TAK-700 to standard hormone therapy for prostate cancer as compared to the standard hormone therapy alone.  
Diagnosis: Prostate Cancer
Principal Investigator: Daniel Shevrin, MD
IRB Approval Number: EH14-055
Sponsor: Southwest Oncology Group (SWOG)
Contact: Interested patients should contact research nurse Tara Flanagan at 847.570.1768
Open to Enrollment: Yes

Astellas ONC-MA-1004: A Prospective Observational Cohort Study of Patients with Castration-Resistant Prostate Cancer (CRPC) in the United States (TRUMPET)
Aims: The purpose of this study to to describe patterns of care, disease assessment methods, treatment decisions, treatment settings, physician referral patterns and to find out how your CRPC symptoms have improved while on therapy.
Principal Investigator: Daniel Shevrin, MD
IRB Approval Number: EH15-219
Sponsor: Astellas Scientific and Medical Affairs
Contact: Interested patients should contact research nurse Tara Flanagan at 847.570.1768
Open to Enrollment: Yes

Janssen 64091742PCR2001 A Phase 2 Efficacy and Safety Study of Niraparib in Men with Metastatic Castration Resistant Prostate Cancer and DNA-Repair Anomalies.
Aims: The main purpose of this study is to see if niraparib is useful to treat men with advanced prostate cancer. The safety of niraparib will also be studied.
Principal Investigator: Daniel Shevrin, MD
IRB Approval Number: EH16-364
Sponsor: Janssen Research and Development, LLC
Contact: Interested patients should contact research nurse Tara Flanagan at 847.570.1768
Open to Enrollment: Yes

UC13-0970: A Phase I/II Trial of Enzalutamide Plus Glucocorticoid Receptor Antagonist Mifepristone for Patient with Metastatic Castration Resistant Prostate Cancer (CRPC)
Aims: The purpose of this study is to see if mifepristone can be safely and effectively added to enzalutamide to treat prostate cancer.
Principal Investigator: Daniel Shevrin, MD
IRB Approval Number: EH17-189
Sponsor: University of Chicago
Contact: Interested patients should contact research nurse Tara Flanagan at 847.570.1768
Open to Enrollment: Yes